A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2015
At a glance
- Drugs AVE 8112 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 05 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Apr 2015 Planned End Date changed from 1 Sep 2013 to 1 Jun 2015, according to to ClinicalTrials.gov record.
- 07 Apr 2015 Planned primary completion date changed from 1 Sep 2013 to 1 Jun 2015, according to to ClinicalTrials.gov record.